Boosting global competitiveness through clinical trial collaboration and information exchange
[by Yu, Suin] CLIPS BnC, a CRO-based novel drug research and development (R&D) company, announced on May 20 that it has signed a memorandum of understanding (MOU) with Indonesian CRO PT Equilab International (hereinafter referred to as EQL) for mutual cooperation in the field of clinical trials.
This agreement established a strategic partnership between the two organizations with the objective of advancing clinical trial capabilities and enhancing global competitiveness. Under the agreement, the two companies aim to strengthen domestic and international outreach and increase external visibility through the establishment of a mutual cooperation framework, the exchange of clinical trial-related information, the organization of joint events, and the identification of joint research initiatives and projects.
In particular, the two companies intend to exchange information and materials essential for conducting clinical trials while fostering knowledge sharing and network strengthening through the joint operation of various programs such as educational sessions, seminars, and forums. Through these efforts, they aim to actively share expertise and resources, thereby creating synergistic effects across all aspects of clinical trial activities.
“This agreement holds special meaning as it will further enhance our expertise in the clinical trial field and lay the foundation for creating a world-class research environment,” said Ji Jun-hwan, CEO of CLIPS BnC. “We will create a sustainable model of cooperation by leveraging our respective strengths,” he added.